Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)

Abstract

Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful. Objective The primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis). Methods Evidence‐based recommendations were formulated using a quasi‐Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts. Results Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer. Conclusion This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

“…Comorbidities could influence the treatment strategy (14). Figure 2 lists selected therapeutics for adult systemic psoriasis with comorbidities (74)(75)(76)(77). Treatment should be tailored to meet the needs of patients (Figure 2).…”

The impact of autoimmune systemic inflammation and associated medications on male reproductive health in patients with chronic rheumatological, dermatological, and gastroenterological diseases: A systematic review

“…In fact, qualitative‐quantitative interactions between drugs and disease cannot be excluded, making any initiative of clinical appropriateness difficult. These considerations also highlight the need to introduce sperm cryopreservation procedures for AD patients 98,99 . Sperm preservation in liquid nitrogen is common practice in case of cancer, and it is recommended to patients before surgery or before starting each therapy potentially damaging, also transiently, the quality of semen 100 …”

Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations

“…The rates per 100 PY of patients with serious gastrointestinal adverse events in the pooled dataset were 0.80 for tildrakizumab 100 mg and 0.43 for tildrakizumab 200 mg, and thus infrequent. Recent expert recommendations have suggested that tildrakizumab can be considered effective and well tolerated in patients with inactive and active IBD, even if the evidence level is low [32].…”